Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Icodec vs Insulin Degludec in Type 2 Diabetes
NCT04795531Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Once weekly insulin icodec + once daily placebo with Once weekly placebo and once daily insulin degludec (2 arms). Primary endpoint: Change in Glycated Haemoglobin at 26 weeks. Started Mar 2021; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04795531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795531.